July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Artificial tear with in situ gelling properties for the treatment of dry eye disease
Author Affiliations & Notes
  • Duygu Acar
    Innovation, Therapy and Pharmaceutical Development in Ophthalmology Research Group (InnOftal), Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain
  • Irene Teresa Molina-Martínez
    Innovation, Therapy and Pharmaceutical Development in Ophthalmology Research Group (InnOftal), Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain
    Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III, Madrid, Spain
  • José Javier López-Cano
    Innovation, Therapy and Pharmaceutical Development in Ophthalmology Research Group (InnOftal), Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain
  • Jose M Benitez Del Castillo
    Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III, Madrid, Spain
    Ocular Surface and Inflammation Unit, San Carlos Clinical Hospital, Madrid, Spain
  • Rocio Herrero-Vanrell
    Innovation, Therapy and Pharmaceutical Development in Ophthalmology Research Group (InnOftal), Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain
    Sanitary Research Institute of the San Carlos Clinical Hospital (IdISSC) and the Ocular Pathology National Net (OFTARED) of the Institute of Health Carlos III, Madrid, Spain
  • Footnotes
    Commercial Relationships   Duygu Acar, None; Irene Molina-Martínez, None; José López-Cano, None; Jose Benitez Del Castillo, None; Rocio Herrero-Vanrell, None
  • Footnotes
    Support  This study was supported by the EDEN Project (642760; MSCA-ITN-2014-EJD; Horizon 2020) granted by the European Commission; FEDER-CICYT FIS-PI17/00079 and FIS-PI17/00466; and the Research Group UCM 920415 (InnOftal).
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3302. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Duygu Acar, Irene Teresa Molina-Martínez, José Javier López-Cano, Jose M Benitez Del Castillo, Rocio Herrero-Vanrell; Artificial tear with in situ gelling properties for the treatment of dry eye disease. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3302.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Artificial tears are commonly employed in the treatment of dry eye disease (DED); though current formulations in the market generally have a short ocular residence time and require repeated daily administration. The purpose of this study was to design and characterize an artificial tear formulation with in situ gelling properties, with the aim of extending the ocular residence time; and evaluate its tolerance in animals. The formulation incorporated components with antioxidant and osmoprotectant properties for their potential beneficial effects in DED treatment.

Methods : An unpreserved artificial tear formulation containing the in situ gelling polymer gellan gum, hydroxypropyl methylcellulose, levocarnitine, vitamin C, trehalose, borates and electrolytes was prepared. The formulation was characterized in terms of pH, osmolarity, surface tension, and viscosity. Once prepared, the formulation was put in contact with a simulated tear fluid, and the rheological properties were evaluated. In vivo tolerance studies were performed in six male New Zealand white rabbits (one eye of each animal was used as control), with macroscopic evaluation of animal discomfort and the ocular surface according to clinical signs, and in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Visual Research.

Results : The formulation presented approximately neutral pH (7.06 ± 0.01), an osmolarity of 275.80 ± 0.35 mOsm/L , and a surface tension of 46.97 ± 0.50 mN/m (at 33°C). The viscosity of the artificial tear measured at 33°C had a mean value of 3.64 ± 0.02 mPa.s within the shear rate interval of 200-1000 s-1. After contact with the simulated tear fluid, gel behavior (G’>G’’) with viscoelastic properties was observed (with a stress threshold of 1.64 ± 0.01 Pa for deformation). The dynamic viscosity of the gel at high shear rates (800-1000 s-1) was in the interval of 2.80-3.00 mPa.s. No discomfort or clinical signs (grade 0) were observed in rabbits throughout the in vivo tolerance studies.

Conclusions : The results demonstrated that the artificial tear developed in this study has suitable physicochemical properties for topical ophthalmic administration, and is well tolerated in animals. The rheological data suggest that the formulation behaves as an in situ gelling system, which could provide extended ocular residence time after topical ophthalmic administration in DED treatment.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×